BrandWikiReturn

Christian Karsten Hansen

Christian Karsten Hansen (born 18 August 1966) is a Danish biotechnology entrepreneur, investor and inventor, with work in new drugs, molecular biology and biochemistry.

Personal background

Originally from Copenhagen (Denmark), he spent his childhood in Antwerp, Belgium and Caracas, Venezuela before completing high school at Sorø Academy in 1984. Following graduation as MSc chemical engineering from the Technical University of Denmark in 1989,[1] PhD work in molecular biology and biochemistry was conducted at the Pasteur Institute,[2][3][4] France and the University of Salamanca,[5] Spain. He also completed an MBA from the Edinburgh Business School, Scotland.[6]

Professional background

Hansen held positions as senior scientist and director of intellectual property management at Novo Nordisk 1992–1999, and was a member of Enzyme Research Management.[6] He co-founded one of the early Danish biotechnology companies, Profound Pharma,[7][8] in 1999, with Jan Møller Mikkelsen,[9] and remained co-CEO thereof until its acquisition by Maxygen in 2000.[10] In 2001, he co-founded the investment firm Nordic Biotech Advisors,[1][11] subsequently renamed NB Capital.[12][13][14][15][16][17] Also in 2001, he founded C Hansen Invest.

Since 2001, Hansen has co-founded and/or been a board member of numerous privately held and listed biotechnology companies including Osteologix,[18][19] Nuevolution,[15][20] Curalogic,[6] Forward Pharma,[21] Rose Pharma,[22] Poalis,[15] Aditech Pharma, Veloxis Pharmaceuticals,[23] H Pharmaceuticals, Isar Pharma,[24] and ParaTech.[25]

Patents

Hansen has filed numerous patent applications in the fields of genetics of bacteria, cellulases and other enzymes, osteoporosis, and protein engineering and uses of biopharmaceuticals. He is named as inventor of issued European patents 510091,[26] 1250154,[27] 1425304,[28] 1534305,[29] 1622629,[30] 1622630,[31] 1732575,[32] 1745791[33] 2266584[34] and 2266585,[35] and US patents 5,843,720,[36] 5,916,796,[37] 6,066,473,[38] 6,555,660,[39] 6,646,110,[40] 6,831,158,[41] 7,230,081,[42] 7,232,562,[43] 7,504,237,[44] 7,550,565,[45] 7,550,566,[46] 7,595,342,[47] 7,696,153[48] and 8,541,471.[49]

Various compounds from these companies and patents are in mid and late stages of clinical development.[50][51][52][53]

References

  1. Festglad venturekapitalist – Diverse Berlingske Business, Business.dk, 10 November 2005, retrieved 10 November 2011^
  2. C K Hansen, B Diderichsen, P L Jørgensen. celA from Bacillus lautus PL236 encodes a novel cellulose-binding endo-beta-1,4-glucanase Journal of Bacteriology, June 1992^
  3. Jørgensen Per L., Hansen Christian K., Poulsen Gitte B., Diderichsen Børge. Gene : In vivo genetic engineering: homologous recombination as a tool for plasmid construction Gene, 1990^
  4. Jørgensen Per L., Hansen Christian K. Gene : Multiple endo-β-1,4-glucanase-encoding genes from Bacillus lactus PL236 and characterization of the celB gene Gene, 1990^
  5. Christian K. Hansen. FEBS Letters : Fibronectin type III-like sequences and a new domain type in prokaryotic depolymerases with insoluble substrates FEBS Letters, 1992^
  6. Archived copy retrieved 17 January 2011^
  7. Rose Pharma – Board Gastrotechpharma.com, retrieved 10 November 2011^
  8. Speed, aggression, surprise! Mva.org, retrieved 10 November 2011^
  9. Dansk bioteks Lance Armstrong – Navne Berlingske Business, Business.dk, 3 August 2010, retrieved 10 November 2011^
  10. Maxygen Reports 2000 Third quarter Financial Results. – Free Online Library Thefreelibrary.com, retrieved 10 November 2011^
  11. Medicon Valley Patent Guide retrieved 2011-01-17^
  12. NB Capital NB Capital, retrieved 10 November 2011^
  13. Vækstfonden – Portefølje Vf.dk, retrieved 10 November 2011^
  14. European Biotechnology News :: Nordic biotech gets Euro41.5m fund Eurobiotechnews.eu, retrieved 10 November 2011^
  15. Danish venture capital company Nordic Biotech raises second biotech venture fund (in English) Mva.org, retrieved 10 November 2011^
  16. Discover Relevant Business Information venturebeatprofiles.com, retrieved 17 January 2011^
  17. Christian Hansen PhD. NB Capital ApS: Private Company Information – BusinessWeek Investing.businessweek.com, retrieved 10 November 2011^
  18. 2005 Archives Osteologix, 29 November 2004, retrieved 10 November 2011^
  19. Archived copy retrieved 17 January 2011^
  20. Biotech companies in Medicon Valley popular among investors – Invest in Denmark Investindk.com, 30 October 2007, retrieved 10 November 2011^
  21. Christian Hanse Forward-pharma.com, retrieved 10 November 2011^
  22. Rose Pharma retrieved 2011-01-14^
  23. Medicon Valley Financing Guide retrieved 2011-01-17^
  24. Isar Pharma K/S: News Release Marketwire, Marketwire.com, retrieved 10 November 2011^
  25. Board Members para-tech.dk, retrieved 2017-07-28^
  26. Espacenet – Bibliographic data^
  27. espacenet – Bibliographic data V3.espacenet.com, 23 October 2002, retrieved 10 November 2011^
  28. espacenet – Bibliographic data V3.espacenet.com, 9 June 2004, retrieved 10 November 2011^
  29. espacenet – Original document V3.espacenet.com, retrieved 10 November 2011^
  30. Espacenet – Bibliographic data^
  31. Espacenet – Bibliographic data^
  32. espacenet – Bibliographic data V3.espacenet.com, 20 December 2006, retrieved 10 November 2011^
  33. Espacenet – Bibliographic data^
  34. Espacenet – Bibliographic data^
  35. Espacenet – Bibliographic data^
  36. Introduction of DNA into bacillus strains by conjugation – US Patent 5843720 Description Patentstorm.us, retrieved 10 November 2011^
  37. Enzyme exhibiting cellulase activity – US Patent 5916796 Full Text Patentstorm.us, retrieved 10 November 2011^
  38. Introduction of DNA into bacillus strains by conjugation – US Patent 6066473 Description Patentstorm.us, retrieved 10 November 2011^
  39. G-CSF conjugates – US Patent 6555660 Full Text Patentstorm.us, retrieved 10 November 2011^
  40. G-CSF polypeptides and conjugates – US Patent 6646110 Full Text Patentstorm.us, retrieved 10 November 2011^
  41. G-CSF conjugates – US Patent 6831158 Full Text Patentstorm.us, retrieved 10 November 2011^
  42. Interferon gamma conjugates – US Patent 7230081 Full Text Patentstorm.us, retrieved 10 November 2011^
  43. E38N interferon gamma polypeptide variants – US Patent 7232562 Full Text Patentstorm.us, retrieved 10 November 2011^
  44. Polynucleotides encoding interferon gamma polypeptides – US Patent 7504237 Full Text Patentstorm.us, retrieved 10 November 2011^
  45. G-CSF conjugates – US Patent 7550565 Full Text Patentstorm.us, retrieved 10 November 2011^
  46. G-CSF conjugates – US Patent 7550566 Full Text Patentstorm.us, retrieved 10 November 2011^
  47. Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions – US Patent 7595342 Full Text Patentstorm.us, retrieved 10 November 2011^
  48. G-CSF conjugates – US Patent 7696153 Full Text Patentstorm.us, retrieved 10 November 2011^
  49. Water-soluble strontium salts for use in treatment of cartilage and/Or bone conditions - US Patent 8541471 Full Text www.patentstorm.us, retrieved 6 June 2022^
  50. News Osteologix, 30 March 2009, retrieved 10 November 2011^
  51. {{ClinicalTrialsGov|NCT00409032|A Dose-response Study With Strontium Malonate in Postmenopausal Women}}^
  52. Treatment of Neutropenia, G-CSF, Neutrophils, Chemotherapy, Protein Therapeutics, Pegylated, Clinical Trial, Neupogen, Neulasta, Blood, Bone Marrow, Breast cancer, Lung cancer, Lymphomas, Leukemias Maxygen.com, retrieved 10 November 2011^
  53. {{ClinicalTrialsGov|NCT00501332|Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy}}^